Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.36 |
| ▸ | SPR | P35270 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.32 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.32 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL541766 | 0.94 | HRH4 (0.42) | SYKHRH4SPRHSD11B1CXCR1 | |
| SCHEMBL541726 | 0.94 | HRH4 (0.42) | SYKHRH4SPRHSD11B1CXCR1 | |
| SCHEMBL15397192 | 0.88 | SYK (0.41) | SYKSPRHSD11B1CNR2 | |
| SCHEMBL541767 | 0.87 | HRH4 (0.42) | HRH4CXCR1CXCR2JAK2JAK1 | |
| SCHEMBL541727 | 0.87 | HRH4 (0.42) | HRH4CXCR1CXCR2JAK2JAK1 | |
| SCHEMBL541417 | 0.82 | SYK (0.41) | SYKHRH4CNR2CXCR1CXCR2 | |
| SCHEMBL541503 | 0.82 | SYK (0.41) | SYKHRH4CNR2CXCR1CXCR2 | |
| SCHEMBL541418 | 0.82 | SYK (0.41) | SYKHRH4CNR2CXCR1CXCR2 | |
| SCHEMBL541504 | 0.82 | SYK (0.41) | SYKHRH4CNR2CXCR1CXCR2 | |
| SCHEMBL15397160 | 0.82 | MAPK8 (0.37) | SYKHRH4HSD11B1MAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130310373-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310373-A1 | PYRIMIDINE COMPOUND | CNR2, CNR1, P2RY2 | SYK 1240/4885HRH4 47/4885SPR 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.